Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GlyphAgo dose-ranging study in generalized anxiety disorder with insomnia symptoms
ACTRN12626001128381Phase 2Not yet recruiting
- Sponsor
- Seaport Therapeutics
- Start
- Sep 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of LYT-320 in generalized anxiety disorder (GAD) (2 arms), sponsored by Seaport Therapeutics. Primary endpoint: Change in insomnia symptoms. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
LYT-320
03
Conditions
generalized anxiety disorder (GAD)
Beyond the preview
Go deeper on ACTRN12626001128381.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12626001128381.